417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study

Background

According to the NCCN guidelines, bevacizumab is recommended drug for recurrent malignant glioma (rMG). Anlotinib is a multitarget tyrosine kinase inhibitor that can inhibit tumor angiogenesis and tumor cell growth. We report results from this retrospective study to determine the efficacy and tolerability of Anlotinib as a treatment for rMG.

Methods

A total of 18 eligible patients who relapsed from the standard chemoradiotherapy regimen (TMZ and radiotherapy) after surgery because of tumor located in the eloquent brain areas were enrolled in this study between May 2020 and June 2022. Patients were subjected to a concurrent treatment of Anlotinib (12mg qd) until disease progression or intolerable toxicity. Efficacy was evaluated using Response Assessment in Neuro-Oncology criteria for high-grade glioma. Safety was assessed using NCI-CTCAE 5.0. Survival was estimated with the Kaplan-Meier curve and log-rank test.

Results

In total, 18 (6 male, 12 female) patients with recurrent malignant glioma were enrolled. The disease control rate was 88.9% (16/18) and the objective response rate was 31.6% (6/18). The 6-month PFS rates were 66.7% and the mPFS was NE. The most common treatment-related adverse events were hand-foot syndrome (44.4%), Weakness(33.3%), hypertension (27.8%) and there were no Grade ≥3 toxicities.

Conclusions

Anlotinib was effective in terms of ORR, and DCR, and was well tolerated. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib for the treatment of rMG.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.